8-K: Dermata Therapeutics Announces 1-for-10 Reverse Stock Split to Boost Share Price

Dermata Therapeutics, Inc. will implement a one-for-10 reverse stock split of its common stock effective August 1, 2025, to adjust its share price and maintain Nasdaq listing compliance.

Summary

• Dermata Therapeutics, Inc. filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation on July 30, 2025.
• This amendment will effect a one-for-10 (1:10) reverse stock split of the company's issued and outstanding shares of common stock.
• The reverse stock split will become effective at 12:01 a.m. Eastern Time on August 1, 2025.
• The company anticipates its common stock will begin trading on Nasdaq on a reverse stock split-adjusted basis when the market opens on August 1, 2025, subject to Nasdaq Capital Market approval.
• As a result of the split, every ten (10) shares of common stock issued and outstanding will be converted into one share.
• No fractional shares will be issued; stockholders who would otherwise be entitled to a fractional share will receive a proportional cash payment.
• The par value of the common stock ($0.0001 per share) and the authorized number of shares (250,000,000 common, 10,000,000 preferred, total 260,000,000) will not change.
• All outstanding securities entitling holders to purchase or acquire common stock, including issued and outstanding stock options and warrants, will be adjusted as required by their terms.
• The CUSIP number for the common stock will change to 249845504.
• The company's stockholders granted the Board of Directors discretion to effect the reverse stock split at a ratio of not less than one-for-two (1:2) and not more than one-for-thirty (1:30) at the 2025 Annual Meeting held on July 15, 2025.
• On July 15, 2025, the Board approved and authorized the filing of the Certificate of Amendment to effect the reverse stock split.

Sentiment

Score: 4

Explanation: A reverse stock split is a technical adjustment often necessitated by a low share price, which can be a negative signal. While it helps maintain exchange listing, it does not fundamentally improve the company's business or financial performance. The market often views such actions with caution, as they can sometimes precede further price declines if underlying issues are not addressed.

Positives

• Aims to increase the per-share trading price, potentially helping the company maintain compliance with Nasdaq listing requirements.
• Maintains the percentage interest of stockholders in the company's equity, except for the treatment of fractional shares.
• Adjusts all outstanding securities like options and warrants to reflect the new share structure, ensuring consistency.

Negatives

• Often indicates a low stock price, which can be a sign of underlying financial or operational challenges.
• Does not fundamentally change the company's market capitalization or intrinsic value.
• Can sometimes be perceived negatively by investors, potentially leading to further price declines post-split if market sentiment is poor.

Risks

• The filing does not explicitly list risks. The inherent risk of a reverse stock split is that it does not guarantee a sustained higher stock price or improved market perception, and the stock price could decline again post-split.

Future Outlook

The company anticipates that its common stock will begin trading on Nasdaq on a reverse stock split-adjusted basis when the market opens on August 1, 2025, subject to Nasdaq Capital Market approval.

Management Comments

• The Board approved and authorized the filing of the Certificate of Amendment to effect the Reverse Stock Split.

Industry Context

Reverse stock splits are a common corporate action undertaken by companies, particularly those listed on exchanges like Nasdaq, to increase their per-share trading price. This is often done to meet minimum bid price requirements for continued listing and avoid delisting, which is a standard practice across various industries for companies facing low stock valuations.

Comparison to Industry Standards

• This 1-for-10 reverse stock split is a standard corporate action, frequently employed by companies like Sorrento Therapeutics (SRNE) or Sundial Growers (SNDL) in the past, to regain compliance with exchange minimum bid price requirements.
• The decision to implement a reverse split, and the chosen ratio within a Board-approved range (1:2 to 1:30), aligns with typical strategies seen across various small-cap and biotech companies aiming to maintain their public listing status.
• The adjustment of outstanding options and warrants is also a standard procedure to ensure equity and contractual obligations are maintained post-split, comparable to actions taken by companies such as Athersys, Inc. (ATHX) during similar corporate restructurings.

Corporate Governance

Stakeholder Impact

• Shareholders: Their number of shares will decrease by a factor of ten, but their percentage ownership will remain the same (except for fractional shares, which will be cashed out). The per-share price is expected to increase proportionally.
• Warrant and Option Holders: Their outstanding securities will be adjusted to reflect the new share count and exercise prices, ensuring their rights are maintained.

Next Steps

• Common stock to begin trading on Nasdaq on a reverse stock split-adjusted basis when market opens on August 1, 2025, subject to Nasdaq approval.
• Stockholders entitled to fractional shares will receive a proportional cash payment.

Key Dates

Keywords

Dermata Therapeutics, DRMA, Reverse Stock Split, Common Stock, Nasdaq Capital Market, Corporate Action, Share Adjustment, CUSIP Change, SEC Filing, 8-K